vom 13.01.2020

Fellowship programme for young cancer researchers: call for applications now open

The National Center for Tumour Diseases (NCT) Heidelberg, in cooperation with the German Cancer Research Centre (DKFZ), the Medical Faculty of Heidelberg and the Heidelberg University Hospital (UKHD), has created the "Heidelberg School of Oncology" (HSO), a junior researcher programme consisting of regular advanced training events and the newly revised HSO² fellowship programme. Young scientists and physicians can now apply for the two-year HSO² programme to work on cancer research projects in the fields of "clinical studies" and "digital oncology".

The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg (UKHD) and the German Cancer Aid (DKH).


From 15 January to 15 March 2020, doctors and scientists can submit their application documents for the HSO2 programme for young scientists online.

The "Heidelberg School of Oncology" is a training programme for cancer researchers at an early stage of their careers. It consists of regular seminars, events, and the HSO² fellowship programme. HSO² aims at young physicians and scientists who are interested in a career in patient-oriented cancer research. "We would like to intensify the exchange between the different professional groups in cancer medicine: Clinicians will gain a better insight into the needs of basic research and scientists will deepen their knowledge of clinical application," says Stefan Fröhling, acting managing director at NCT Heidelberg and head of the Department of Translational Medical Oncology at DKFZ. With this approach, the NCT Heidelberg hopes to promote research transfer, also known as translational research. The aim is to accelerate the transfer of cancer research results into clinical application in terms of better strategies for cancer diagnostics, treatment, and prevention.

After a successful application for the HSO² , fellows receive funding for their two-year work. Clinically working physicians are released for their research work up to 100 percent of their clinical duties? as required. In addition, fellows may receive limited project resources depending on their project. Two mentors support each HSO² fellow and give advice in career-development topics as well as science-related questions.

For this year's call, the junior cancer researcher programme has been revised. Each call for proposals is now linked to one or two priority topics that will guide the research projects of HSO² fellows. The current call for proposals focuses on the areas of "clinical trials" and "digital oncology".

Application deadline: 15 January to 15 March 2020

Application
Applications are open to scientists and physicians with a medical licence, doctorate, PhD certificate or with equivalent academic achievements. Candidates should be at an early stage of their career: physicians before the end of the medical training (German: Facharztausbildung); scientists up to five years after obtaining their PhD.

Applications in English can be submitted via the HSO² online portal (www.nct-heidelberg.de/hso) and must include the following information in one pdf file:

  • Curriculum vitae including a list of publications
  • Relevant certificates, e.g. doctorate or PhD certificate, medical license, etc.
  • Letter of motivation
  • Contact details of two references

Contact
National Center for Tumor Diseases (NCT) Heidelberg
Im Neuenheimer Feld 460
69120 Heidelberg
hso@nct-heidelberg.de

Images for the press release are available free of charge at
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/Meldungen/Bilder/NCT_191017_0804.jpg

Terms of use for image material for press releases
The use is free of charge. The NCT Heidelberg permits one-time use in connection with reporting on the topic of the press release. Please quote "NCT Heidelberg" as photo credit. The images may only be passed on to third parties after prior consultation with the NCT press office (Tel.: 06221 56 5930, Email: friederike.fellenberg@nct-heidelberg.de). Use for commercial purposes is prohibited.

Press contact:
Dr. Friederike Fellenberg
National Center for Tumor Diseases Heidelberg (NCT)
Press and Public Relations
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-5930
Fax: +49 6221 56-5350
Email: friederike.fellenberg@nct-heidelberg.de
www.nct-heidelberg.de

Dr. Sibylle Kohlstädt
German Cancer Research Center (DKFZ)
Communications and Marketing
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2843
Fax: +49 6221 42-2968
Email: s.kohlstaedt@dkfz.de
www.dkfz.de

Doris Rübsam-Brodkorb
Heidelberg University Hospital and Medical Faculty of the University of Heidelberg
Press and Public Relations
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
Email: doris.ruebsam-brodkorb@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de

National Center for Tumor Diseases Heidelberg (NCT)
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital (UKHD) and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. This is true for diagnosis and treatment, follow-up care or prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here, the patients benefit from an individual treatment plan prepared in interdisciplinary expert rounds, so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, the NCT Heidelberg has maintained a partner site in Dresden. The Hopp Children's Cancer Center (KiTZ) was established in Heidelberg in 2017. The pediatric oncologists at KiTZ work together in parallel structures with the NCT Heidelberg.

German Cancer Research Center (DKFZ)
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. At DKFZ, more than 1,300 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.
DKFZ's Cancer Information Service (KID) provides individual answers to all questions about cancer for patients, the general public, and health care professionals.
Jointly with partners from Heidelberg University Hospital, DKFZ runs the National Center for Tumor Diseases (NCT) located in Heidelberg and Dresden, and, also in Heidelberg, the Hopp Children's Cancer Center (KiTZ). In the German Cancer Consortium (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center at the NCT and DKTK sites is an important contribution to the endeavor of translating promising approaches from cancer research into the clinic in order to improve the chances of cancer patients.
DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Heidelberg University Hospital (UKHD)

Heidelberg University Hospital (UKHD) is one of the most important medical centers in Germany; Heidelberg University's Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 13,000 individuals and are involved in training and qualification. Every year approximately 65,000 patients are treated as inpatients and 56,000 as day patients in more than 50 specialized clinical departments with around 2,000 beds, with more than 1 million patients being treated as outpatients. Together with the German Cancer Research Center and German Cancer Aid, the Heidelberg University Hospital established The National Center for Tumor Diseases (NCT) Heidelberg as the leading oncology center of excellence in Germany. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present 3,700 aspiring physicians and doctors are studying in Heidelberg.